Hepatitis C infection among survivors of childhood cancer

Blood

Volumn 95, Issue 10, 2000, Pages 3065-3070

  Strickland, Donald K ^a   Riely, Caroline A ^b   Patrick, Christian C ^b   Jones Wallace, Dana ^b   Boyett, James M ^b   Waters, Bradford ^b   Fleckenstein, Jaquelyn Fitch ^b   Dean, Patrick J ^b   Davila, Rene ^b   Caver, Tony E ^b   Hudson, Melissa M ^b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ALPHA INTERFERON; RIBAVIRIN;

ADOLESCENT; ADULT; APLASTIC ANEMIA; ARTICLE; BLOOD TRANSFUSION; CANCER SURVIVAL; CHILDHOOD CANCER; DISEASE ASSOCIATION; FEMALE; GENOTYPE; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD;

EID: 18744419247     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.10.3065.010k20_3065_3070     Document Type: Article

References (45)

1. Villano SA, Vlahov D, Nelson KE, Cohn S, Thomas DL. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology. 1999;29:908.
2. Shakil A, Conry-Cantilena C, Alter H, et al. Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features: the Hepatitis C Study Group. Ann Intern Med. 1995;123:330.
3. Yano M, Yatsuhashi H, Inoue O, Inokuchi K, Koga M. Epidemiology and long term prognosis of hepatitis C virus infection in Japan. Gut. 1993; 34(suppl 2):S13.
4. Arico M, Maggiore G, Silini E, et al. Hepatitis C virus infection in children treated for acute lymphoblastic leukemia. Blood. 1994;84:2919.
5. Cesaro S, Petris MG, Rossetti F, et al. Chronic hepatitis C infection after treatment for pediatric malignancy. Blood. 1997;90:1315.
6. Fink FM, Hocker-Schulz S, Mor W, et al. Association of hepatitic C virus infection with chronic liver disease in paediatric cancer patients. Eur J Pediatr. 1993;152:490.
7. Locasciulli A, Alberti A. Hepatitis C virus serum markers and liver disease in children with leukemia. Leuk Lymphoma. 1995;17:245.
8. Locasciulli A, Cavalletto D, Ponlisso P, et al. Hepatitis C virus serum markers and liver disease in children with leukemia during and after chemotherapy. Blood. 1993;82:2564.
9. Locasciulli A, Testa M, Valsecchi MG, et al. Morbidity and mortality due to liver disease in children undergoing allogeneic bone marrow transplantation: a 10-year prospective study. Blood. 1997;90: 3799.
10. Locasciulli A, Testa M, Pontisso P, et al. Prevalence and natural history of hepatitis C infection in patients cured of childhood leukemia. Blood. 1997;90:4628.
11. Hepatitis C: global prevalence. Wkly Epidemiol Rec. 1997;72:341.
12. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology. 1994;19:1513.
13. Carr B, Flickinger J, Lotze M. Hepatobiliary cancers. In DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. Philadelphia: Lippincott-Raven; 1997:1095.
14. Management of hepatitis C. NIH Consens Statement. 1997;15:1.
15. Donahue JG, Munoz A, Ness PM, et al. The declining risk for post-transfusion hepatitis C virus infection. N Engl J Med. 1992;327:369.
16. Esteban JI, Gonzalez A, Hernandez JM, et al. Evaluation of antibodies to hepatitis C virus in a study of transfusion-associated hepatitis. N Engl J Med. 1990;323:1107.
17. Conry-Cantilena C, VanRaden M, Gibble J, et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med. 1996;334:1691.
18. Gordon SC, Kodali VP, Silverman AL, et al. Levels of hepatitis C virus RNA and liver histology in chronic type C hepatitis. Am J Gastroenterol. 1994;89:1458.
19. Nordoy I, Schrumpf E, Elgjo K, et al. Liver disease in anti-hepatitis C virus-positive Norwegian blood donors. Scand J Gastroenterol. 1994;29: 77.
20. Haydon GH, Jarvis LM, Blair CS, et al. Clinical significance of intrahepatic hepatitis C virus levels in patients with chronic HCV infection. Gut. 1998; 42:570.
21. Lucidarme D, Durnas F, Arpurt J, et al. Natural history of hepatitis C: age at the time of the transfusion might be an important predictive factor of progression to cirrhosis. Gastroenterology. 1997; 112:A361.
22. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C: the OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997; 349:825.
23. Vogt M, Lang T, Frosner G, et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med. 1999;341:866.
24. Fournillier-Jacob A, Lunel F, Cahour A, et al. Antibody responses to hepatitis C envelope proteins in patients with acute or chronic hepatitis C. J Med Virol. 1996;50:159.
25. Sato S, Fujiyama S, Tanaka M, et al. IgM and IgA antibodies generated against hepatitis C virus core antigen in patients with acute and chronic HCV infection. Dig Dis Sci. 1994;39:2022.
26. Lechner S, Rispeter K, Meisel H, et al. Antibodies directed to envelope proteins of hepatitis C virus outside of hypervariable region 1. Virology. 1998; 243:313.
27. Serfaty L, Chazouilleres O, Poujol-Robert A, et al. Risk factors for cirrhosis in patients with chronic hepatitis C virus infection: results of a case-control study. Hepatology. 1997;26:776.
28. Oshita M, Hayashi N, Kasahara A, et al. Increased serum hepatitis C virus RNA levels among alcoholic patients with chronic hepatitis C. Hepatology. 1994;20:1115.
29. Bellentani S, Tiribelli C, Saccoccio G, et al. Prevalence of chronic liver disease in the general population of northern Italy: the Dionysos Study. Hepatology. 1994;20:1442.
30. Zein NN, Rakela J, Krawitt EL, Reddy KR, Tominaga T, Persing DH. Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy: Collaborative Study Group. Ann Intern Med. 1996;125:634.
31. Nousbaum J, Pol S, Nalpas B, Landais P, Berthelot P, Brechot C. Hepatitis C virus type 1b (II) infection in France and Italy: Collaborative Study Group. Ann Intern Med. 1995;122:161.
32. Lau JY, Davis GL, Kniffen J, et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet. 1993;341:1501.
33. Vento S, Garofano T, Rezini C, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med. 1998;338:286.
34. Zarski JP, Bohn B, Bastie A, et al. Characteristics of patients with dual infection by hepatitis B and C viruses. J Hepatol. 1998;8:27.
35. Lefrere JJ, Loiseau P, Maury J, et al. Natural history of GBV-C/hepatitis G virus infection through the follow-up of GBV-C/hepatitis G virus-infected blood donors and recipients studied by RNA polymerase chain reaction and anti-E2 serology. Blood. 1997;90:3776.
36. Mauser-Bunschoten EP, Damen M, Zaaijer HL, et al. Hepatitis G virus RNA and hepatitis G virus-E2 antibodies in Dutch hemophilia patients in relation to transfusion history. Blood. 1998;92: 2164.
37. Prati D, Zanella A, Bosoni P, et al. The incidence and natural course of transfusion-associated GB virus C/hepatitis G virus infection in a cohort of thalassemic patients: the Cooleycare Cooperative Group. Blood. 1998;91:774.
38. Skidmore SJ, Collingham KE, Harrison P, Neilson JR, Pillay D, Milligan DW. High prevalence of hepatitis G virus in bone marrow transplant recipients and patients treated for acute leukemia. Blood. 1997;89:3853.
39. Wang JT, Tsai FC, Lee CZ, et al. A prospective study of transfusion-transmitted GB virus C infection: similar frequency but different clinical presentation compared with hepatitis C virus. Blood. 1996;88:1881.
40. Paul IM, Sanders J, Ruggiero F, Andrews T, Ungar D, Eyster ME. Chronic hepatitis C virus infections in leukemia survivors: prevalence, viral load, and severity of liver disease. Blood. 1999;93:3672.
41. Hoofnagle J, Di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med. 1997;336: 347.
42. Tine F, Magrin S, Craxi A, Pagliaro L. Interferon for non-A, non-B chronic hepatitis: a meta-analysis of randomised clinical trials. J Hepatol. 1991; 13:192.
43. Lin R, Roach E, Zimmerman M, Strasser S, Farrell GC. Interferon alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates: results of the first multicentre Australian trial: Australia Hepatitis C Study Group. J Hepatol. 1995;23:487.
44. Carithers RL Jr, Emerson SS. Therapy of hepatitis C: meta-analysis of Interferon alfa-2b trials. Hepatology. 1997;26(3 suppl 1):83S.
45. McHutchinson JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C: Hepatitis Interventional Therapy Group. N Engl J Med. 1998;339:1485.